Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.
Poon DMC, Tan GM, Chan K, Chan MTY, Chan TW, Kan RWM, Lam MHC, Leung CLH, Wong KCW, Kam KKH, Ng CF, Chiu PKF. Poon DMC, et al. Among authors: chan tw. Front Oncol. 2024 Jan 31;14:1345322. doi: 10.3389/fonc.2024.1345322. eCollection 2024. Front Oncol. 2024. PMID: 38357197 Free PMC article. Review.
Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong.
Poon DMC, Wong KCW, Chan TW, Law K, Chan K, Lee EKC, Lee C, Chan M; Hong Kong Society of Uro-Oncology (HKSUO). Poon DMC, et al. Among authors: chan m, chan k, chan tw. Clin Genitourin Cancer. 2018 Oct;16(5):402-412.e1. doi: 10.1016/j.clgc.2018.07.008. Epub 2018 Jul 21. Clin Genitourin Cancer. 2018. PMID: 30126765 Free article.
A Territory-wide, Multicenter, Age- and Prostate-specific Antigen-matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone-sensitive Prostate Cancer.
Teoh JYC, Poon DMC, Lam D, Chan T, Chan MFT, Lee EKC, Law S, Chan K, Cheng NM, Lai KM, Leung CH, Ng CF. Teoh JYC, et al. Clin Genitourin Cancer. 2019 Feb;17(1):e203-e208. doi: 10.1016/j.clgc.2018.10.010. Epub 2018 Oct 27. Clin Genitourin Cancer. 2019. PMID: 30454968
Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study.
Poon DMC, Chan K, Lee SH, Chan TW, Sze H, Lee EKC, Lam D, Chan MFT; Hong Kong Society of Uro-Oncology (HKSUO). Poon DMC, et al. Among authors: chan k, chan tw, chan mft. Prostate Int. 2018 Mar;6(1):24-30. doi: 10.1016/j.prnil.2017.08.001. Epub 2017 Aug 18. Prostate Int. 2018. PMID: 29556486 Free PMC article.
A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer.
Lam BHW, Tsang VHM, Lee MP, Chan K, Liu TC, Ng BYH, Wo BBW, Leung KC, Mui WH, Chan TW, Lam MHC, Siu SWK, Poon DMC. Lam BHW, et al. Among authors: chan k, chan tw. Clin Genitourin Cancer. 2024 Feb;22(1):e75-e85.e1. doi: 10.1016/j.clgc.2023.07.012. Epub 2023 Aug 2. Clin Genitourin Cancer. 2024. PMID: 37604745 Free article.
hnRNPM protects against the dsRNA-mediated interferon response by repressing LINE-associated cryptic splicing.
Zheng R, Dunlap M, Bobkov GOM, Gonzalez-Figueroa C, Patel KJ, Lyu J, Harvey SE, Chan TW, Quinones-Valdez G, Choudhury M, Le Roux CA, Bartels MD, Vuong A, Flynn RA, Chang HY, Van Nostrand EL, Xiao X, Cheng C. Zheng R, et al. Among authors: chan tw. Mol Cell. 2024 May 22:S1097-2765(24)00397-6. doi: 10.1016/j.molcel.2024.05.004. Online ahead of print. Mol Cell. 2024. PMID: 38815579
185 results